How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

865 results for

Endocrine Manifestations of HIV

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

841. Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

that is metastatic or unresectable and unresponsive to conventional chemotherapy and/or radiotherapy Measurable or evaluable disease required Measurable disease defined as bidimensionally measurable lesion on physical exam, x-ray, or MRI Evaluable disease defined as: Unidimensionally measurable lesion on x-ray, scan, or photograph Disease assessable by serial chemistries, tumor markers, or nonspecific scans Disease assessable by functional manifestations (e.g., change in performance status, 10% or greater change (...) No symptomatic hypercalcemia Cardiovascular: No myocardial infarction within 6 months No congestive heart failure No edema No hypotension or hypertension No coronary artery disease No history of arrhythmia No contraindication to the use of pressor agents Pulmonary: FEV1 at least 65% of predicted Other: No significant organ dysfunction No uncontrolled bacterial, viral, or fungal infection No active peptic or duodenal ulcer No psychiatric or seizure disorder No prior solid organ allograft HIV and hepatitis B

1999 Clinical Trials

842. Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed Kaposi's sarcoma (KS) HIV positive Evaluable disease involving the skin and/or viscera At least 5 lesions not previously treated with local therapy if restricted to the skin Pulmonary lesions evaluable by CT scan Gastrointestinal lesions evaluable by visualization or fiberoptic instrumentation Presence of at least one of the following indications for cytotoxic chemotherapy: Pulmonary (...) , or malignancy in complete remission for at least 1 year from the time a response was first documented No severe or life-threatening infection within the past 2 weeks No abnormality that would be scored as grade 3 toxicity except lymphopenia or direct manifestations of KS No known hypersensitivity to interleukin-12 (IL-12) or other compounds known to cross-react with IL-12 No other medical condition that would preclude study entry PRIOR CONCURRENT THERAPY: Biologic therapy: More than 2 weeks since prior

2001 Clinical Trials

843. Heart Disease Risk Factors in Major Depression

means for treatment and prevention. Depressed patients are known to manifest a variety of neuroendocrine changes that predispose to coronary artery disease including hypercortisolism, decreased secretion of growth hormone and a deficiency of sex steroids. A final common denominator of these neuroendocrine abnormalities is insulin resistance. Insulin resistance promotes several changes that would favor hypertension and increased coronary artery disease including increased sodium retention, increased (...) the mechanisms underlying this susceptibility are, and to develop improved means for treatment and prevention. Depressed patients are known to manifest a variety of neuroendocrine changes that predispose to coronary artery disease including hypercortisolism, decreased secretion of growth hormone and a deficiency of sex steroids. A final common denominator of these neuroendocrine abnormalities is insulin resistance. Insulin resistance promotes several changes that would favor hypertension and increased

2000 Clinical Trials

844. Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

by radionuclide bone scan The most recent PSA must be at least 4 ng/mL if no measurable disease is present Ineligible if sole manifestation of progressive disease is an increase in disease-related symptoms Serum testosterone no greater than 50 ng/mL One of the following therapies for maintenance of castrate status required: Must continue on gonadotropin-releasing hormone analogs (e.g., leuprolide or goserelin) to maintain castrate levels of serum testosterone Developed disease progression after (...) not considered currently active if completely treated with less than a 30% risk for relapse No other concurrent uncontrolled illness No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF) except for neutropenic fever No concurrent immunotherapy Chemotherapy: No prior chemotherapy No other concurrent chemotherapy Endocrine therapy: See Disease

2001 Clinical Trials

845. Treatment of Hemochromatosis

inherited disease in this population. Although the molecular pathophysiology remains incompletely understood, a homozygous mutation in the HFE gene (Cys282Tyr) is observed in nearly 100% of clinically confirmed cases. The clinical manifestations of HH are due to inappropriately increased iron absorption with excessive iron deposition in the liver, heart, endocrine organs, and joints. Phlebotomy treatment, with removal of iron contained in the hemoglobin of red cells, is the only effective therapy for HH (...) of excess iron With each blood donation that will be made available for transfusion to other patients, participants will answer the same health history screening questions and undergo the same blood tests given to all regular volunteer blood donors. These include screening for the HIV and hepatitis viruses and for syphilis. Patients who meet height and weight requirements may be asked to consider "double red cell" donations using apheresis. In this procedure, whole blood is collected through a needle

2000 Clinical Trials

846. Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

hypersensitivity reactions (e.g., angioedema, anaphylaxis, or serious dermatological manifestations) or asthmatic attacks requiring hospitalization No prior immune or immunodeficiency disorders (e.g., HIV, sarcoidosis, tuberculosis, rheumatoid arthritis, or autoimmune disorders) No prior seizure disorder requiring continuous medication No active infection No other prior or concurrent malignancy within the past 3 years except surgically treated carcinoma in situ of the cervix or squamous cell or basal cell skin (...) : At least 3 years since prior chemotherapy except topical therapy No concurrent methotrexate or cyclophosphamide Endocrine therapy: At least 45 days since prior corticosteroids No concurrent systemic corticosteroids Radiotherapy: No prior thoracic radiotherapy Surgery: See Disease Characteristics Other: At least 45 days since prior immunosuppressants No investigational agents within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer No concurrent

2000 Clinical Trials

847. S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

of the cervix or adequately treated stage I or II cancer currently in remission HIV negative Hepatitis B surface antigen negative PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since radiotherapy and recovered Surgery: Not specified Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may (...) CHARACTERISTICS: Immunologically diagnosed Waldenstrom's macroglobulinemia (WM) Evaluable quantifiable IgM One of the following criteria must be met: 1) Patient demonstrates clinical symptoms such as fatigue, dizziness, visual inacuity, or hemorrhagic manifestations of WM with anemia, hyperviscosity, thrombocytopenia, or coagulopathies 2) Advanced tumor mass present involving ONE of the following: Extensive lymphadenopathy (greater than 2 cm) Hepato or splenomegaly palpable on clinical examination Marked bone

1999 Clinical Trials

848. Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

of symptomatic coronary artery disease unless cleared after cardiology evaluation Pulmonary: FEV1 at least 60% predicted FEV1/FVC at least 60% Other: HIV negative Hepatitis B surface antigen negative PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No more than 2 prior chemotherapy regimens, including induction Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Contacts and Locations Go to Information from the National (...) or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: up to 65 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: All stages of multiple myeloma Measurable disease manifested by monoclonal serum or urine globulins If nonsecretory, must have malignant plasma cells documented on bilateral bone marrow

2000 Clinical Trials

849. Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia

HIV negative No other active malignancy Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: See Disease Characteristics No concurrent corticosteroids Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 4 weeks since prior major surgery Contacts and Locations Go (...) CHARACTERISTICS: Diagnosis of B-cell chronic lymphocytic leukemia manifested by all of the following: Minimum threshold peripheral lymphocyte count of at least 5,000/mm3 Small to medium sized peripheral blood lymphocytes with no greater than 55% prolymphocytes Bone marrow aspirate and biopsy containing at least 30% lymphoid cells Immunophenotypic and biopsy evaluation of peripheral blood lymphocytes demonstrating monoclonality of B lymphocytes B-cell markers with CD5 antigen (e.g., T-1, T-101) in the absence

2000 Clinical Trials

850. Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

) or progressive lymphadenopathy Progressive lymphocytosis with more than 50% increase over 2-month period or anticipated doubling time of less than 12 months Progressive bone marrow failure as manifested by development or worsening of anemia and/or thrombocytopenia Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids Biopsy proven low-, intermediate-, or high-grade non-Hodgkin's lymphoma Transformed lymphoma allowed Measurable disease required Re-treatment on this study allowed (...) OR Creatinine clearance at least 60 mL/min Cardiovascular: No history of impaired cardiac status, e.g.: Severe coronary artery disease Cardiomyopathy Uncontrolled congestive heart failure Arrhythmia Other: No known AIDS or HIV infection No second malignancy within 5 years except: Adequately treated nonmelanomatous skin cancer In situ cervical cancer Not pregnant or nursing Effective contraception required of fertile patients during and for 2 months after study PRIOR CONCURRENT THERAPY: No concurrent therapy

1999 Clinical Trials

851. Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

participation No HIV infection No AIDS PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplantation Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy (8 weeks for mitomycin or nitrosoureas) and recovered Endocrine therapy: See Disease Characteristics No concurrent steroids No concurrent hormonal contraceptives Radiotherapy: At least 4 weeks since prior radiotherapy and recovered Surgery: Not specified Other: No other concurrent therapy Contacts (...) : 10% or more loss of body weight within the past 6 months Extreme fatigue Fever greater than 100 degrees Fahrenheit without evidence of infection Night sweats Massive (greater than 6 cm below left costal margin) or progressive splenomegaly Massive (greater than 10 cm in longest diameter) or progressive lymphadenopathy Progressive lymphocytosis with an increase of more than 50% over a 2-month period or anticipated doubling time of less than 12 months Progressive bone marrow failure as manifested

1999 Clinical Trials

852. Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Diagnosis of B-cell chronic lymphocytic leukemia (CLL) manifested by all of the following: Threshold peripheral lymphocyte count greater than 5000/mm3 Small to moderate peripheral lymphocytes with no greater than 55% prolymphocytes Peripheral lymphocyte count less than 15,000/mm3 At least 30% lymphoid cells in bone marrow (...) Monoclonality of B lymphocytes Active disease by at least one of the following criteria: Weight loss of at least 10% within the past 6 months or prolonged fever or night sweats without evidence of infection Progressive marrow failure (stage III or IV disease) manifested by Hemoglobin less than 11 g/dL (anemia) AND/OR Platelet count less than 100,000/mm3 (thrombocytopenia) Autoimmune anemia and/or thrombocytopenia minimally responsive to corticosteroid therapy Massive or progressive splenomegaly Massive

1999 Clinical Trials

853. Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

6 months Failed prior steroid therapy (i.e., unable to achieve sustained platelet count greater than 75,000/mm3) No drug associated ITP No B cell malignancies No evidence of disseminated intravascular coagulation (DIC) --Prior/Concurrent Therapy-- Endocrine therapy: Concurrent steroids allowed as long as platelet count is less than 75,000/mm3 and dose is not changed within past 2 weeks or during study Other: No other concurrent medical therapy for immune thrombocytopenia purpura (ITP) At least 2 (...) weeks since prior therapy for ITP (except steroids) At least 4 weeks since prior cyclosporine --Patient Characteristics-- Performance status: ECOG 0-2 Life expectancy: At least 6 months Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No congestive heart failure or symptomatic coronary insufficiency Other: No clinically significant bleeding (i.e., other than mild mucosal bleeding or petechiae) No sepsis or fever No active infection requiring therapy No active chronic viral infection HIV

2000 Clinical Trials

854. Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma

by physical exam, radiograph, CT, or MRI (sonography and barium studies alone not acceptable) Measurable liver disease defined as: Mass greater than 3.5 cm on CT, MRI, or ultrasound OR Histologically documented lymphomatous hepatomegaly more than 5 cm below the costal margin The following disease manifestations are not considered measurable: Ascites or pleural effusion Bony disease (lytic lesions on x-ray should be documented and followed) CNS lesions Bone marrow involvement No lymphomatous involvement (...) or congestive heart failure (CHF) No active cardiac problems, including compensated CHF or angina Other: HIV negative No other malignancy within the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the cervix No active uncontrolled bacterial, viral, or fungal infection No other serious medical illness that would limit survival to less than 2 years No psychiatric condition that would preclude informed consent or compliance No uncontrolled duodenal ulcer Not pregnant

1999 Clinical Trials

855. Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

-LET photon therapy Phase 2 Detailed Description: OBJECTIVES: I. Determine the response rate and disease free survival of HIV seronegative patients with diffuse small noncleaved cell lymphoma or L3 acute lymphocytic leukemia when treated with high intensity, brief duration combination chemotherapy: alternating courses of ifosfamide/cytarabine/etoposide and cyclophosphamide/doxorubicin, each with methotrexate/vincristine/dexamethasone. II. Determine the toxicity of these regimens in HIV negative (...) involvement Disease labeled L3 but also manifested by lymphadenopathy must be evaluated as is lymphoma (see above) PATIENT CHARACTERISTICS: Age: 15 and over Performance status: Any status Life expectancy: At least 2 years Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times normal (unless further elevation is directly attributable to malignancy) Renal: Creatinine no greater than 1.5 times normal (unless further elevation is directly attributable to malignancy) Cardiovascular

1999 Clinical Trials

856. Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

cord damage. Clinically significant untreated renal or endocrine disease. Uncontrolled hypotension or hypertension manifested by systolic blood pressure >170 or <90 mm Hg or diastolic blood pressure >100 or <50 mm Hg (if stress is suspected, participants will be retested under basal conditions). Patients with any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate >100 bpm) at rest despite medical or device therapy, or any history of spontaneous or induced (...) . History of HIV infection or active, untreated pelvic or urinary tract infection including, sexually transmitted diseases such as chlamydia, genital herpes, gonorrhea, or syphilis. Major pelvic surgery that may have caused nerve damage, including: vulvectomy, circumcision, colostomy, cystostomy, or serious bladder, rectal, or abdominal surgery. Neurological impairment due to diabetes, stroke, pelvic nerve damage secondary to trauma, cancer treatments, myasthenia gravis, multiple sclerosis or spinal

2002 Clinical Trials

857. Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

STATUS: ECOG 0-2. LIFE EXPECTANCY: At least 6 months. HEMATOPOIETIC: Platelet count greater than 150,000/mm(3). HEPATIC: Bilirubin less than 2.0 mg/dL. RENAL: Creatinine less than 2.0 mg/dL. CARDIOVASCULAR: No history of congestive heart failure with an LVEF less than 40%. PULMONARY: No chronic obstructive pulmonary disease. No other chronic pulmonary disease with PFTs less than 50% predicted for age. OTHER: IF HIV POSITIVE: Must have CD4 cell count greater than 500/mL and, No clinical manifestations (...) . Sarcoma must have either cutaneous lesions amenable to direct measurement or deeper lesions that can be measured on CT or MRI scans. PRIOR/CONCURRENT THERAPY: At least 2 months since any regional therapy to the affected extremity. BIOLOGIC THERAPY: At least 1 month since Biologic Therapy. CHEMOTHERAPY: At least 1 month since chemotherapy. ENDOCRINE THERAPY: Not specified. RADIOTHERAPY: At least 1 month since radiotherapy. SURGERY: Not specified. PATIENT CHARACTERISTICS: AGE: 18 and over. PERFORMANCE

1999 Clinical Trials

858. Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

than 1.5 times upper limit of normal (ULN) together with alkaline phosphatase greater than 2.5 times ULN No active hepatitis B or C Renal: Creatinine normal Cardiovascular: Ejection fraction normal by MUGA or echocardiogram No active heart disease No prior myocardial infarction or other manifestation of coronary artery disease Other: More than 1,000 calories/day oral intake HIV negative No active serious medical or psychiatric disease No other prior or concurrent malignancy except basal cell skin (...) doxorubicin or 450 mg/m2 prior epirubicin Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the brain or marrow-bearing pelvis Prior radiotherapy to lower pelvis allowed if the upper border of the radiotherapy field is below the upper border of the acetabulum No other prior radiotherapy to the pelvis Surgery: At least 2 weeks since prior major surgery Other: No other concurrent anti-cancer therapy Contacts and Locations Go to Information from the National Library of Medicine To learn

2001 Clinical Trials

859. Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen

) for at least 5 years and been under physician care for at least 6 months prior to enrollment in trial. Eligible candidates will have poorly controlled IDDM and manifest signs and symptoms severe enough to be incapacitating. These symptoms can include episodes of hypoglycemic unawareness (failure to recognize blood glucose levels < 54 mg/dl) or episodes requiring the assistance of others. Candidates may have poor diabetes control despite intensive insulin therapy (HbA1c > 8.0%). Creatinine clearance should (...) ulcer disease, gall stones, or portal hypertension Abnormal liver function tests Presence of panel reactive antibodies > 20% Creatinine clearance < 60 ml/min HbA1c > 12% Serological evidence of HIV, HbsAg, or HCV Anemia (hemoglobin < 12.0) Any condition or circumstance, including psychogenic factors, that preclude therapeutic compliance or otherwise make it unsafe to undergo an islet cell transplant. PSA > 4 in males Contacts and Locations Go to Information from the National Library of Medicine

2001 Clinical Trials

860. Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression

insulin-dependent diabetes mellitus (IDDM) and manifest signs and symptoms severe enough to be incapacitating. These symptoms can include episodes of hypoglycemic unawareness (failure to recognize blood glucose levels < 54 mg/dl) or episodes requiring the assistance of others. Candidates may have poor diabetes control despite intensive insulin therapy (HbA1c > 8.0%). Creatinine clearance should be > 60 ml/min) Body Mass Index should be less than 26 Women of child-bearing age must have a negative (...) antibodies > 20% Creatinine clearance < 60 ml/min HbA1c 12% Serological evidence of HIV, HbsAg, or HCV Anemia (hemoglobin < 12.0) Any condition or circumstance, including psychogenic factors, that preclude therapeutic compliance or otherwise make it unsafe to undergo an islet cell transplant. PSA > 4 in males Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>